These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17337289)

  • 1. Influence of sample type on soluble CD40 ligand assessment in patients with acute coronary syndromes.
    Weber M; Rabenau B; Stanisch M; Nef HM; Möllmann H; Elsässer A; Mitrovic V; Heeschen C; Hamm C
    Thromb Res; 2007; 120(6):811-4. PubMed ID: 17337289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different behaviour of soluble CD40L concentrations can be reflected by variations of preanalytical conditions.
    Wenzel F; Baertl A; Zimmermann N; Hohlfeld T; Giers G; Oldenburg J; Assert R
    Clin Hemorheol Microcirc; 2008; 39(1-4):417-22. PubMed ID: 18503154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of sample type and storage conditions on soluble CD40 ligand assessment.
    Weber M; Rabenau B; Stanisch M; Elsaesser A; Mitrovic V; Heeschen C; Hamm C
    Clin Chem; 2006 May; 52(5):888-91. PubMed ID: 16527885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk.
    Ahn ER; Lander G; Jy W; Bidot CJ; Jimenez JJ; Horstman LL; Ahn YS
    Thromb Res; 2004; 114(2):143-8. PubMed ID: 15306157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble CD40L levels are regulated by the -3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome.
    Mälarstig A; Lindahl B; Wallentin L; Siegbahn A
    Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1667-73. PubMed ID: 16627810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of pre-analytical and analytical factors on soluble CD40L measurements.
    Varo N; Nuzzo R; Natal C; Libby P; Schönbeck U
    Clin Sci (Lond); 2006 Nov; 111(5):341-7. PubMed ID: 16856875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of elevated serum soluble CD40 ligand on the prognostic value in patients with acute coronary syndromes.
    Yan JC; Zhu J; Gao L; Wu ZG; Kong XT; Zong RQ; Zhan LZ
    Clin Chim Acta; 2004 May; 343(1-2):155-9. PubMed ID: 15115688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble CD40L: risk prediction after acute coronary syndromes.
    Varo N; de Lemos JA; Libby P; Morrow DA; Murphy SA; Nuzzo R; Gibson CM; Cannon CP; Braunwald E; Schönbeck U
    Circulation; 2003 Sep; 108(9):1049-52. PubMed ID: 12912804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Serum sCD40L detection for risk evaluation of acute coronary syndromes].
    Xu BL; Bei CH; Wang R; Lei XX
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Nov; 26(11):1656-7. PubMed ID: 17121725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study.
    de Lemos JA; Zirlik A; Schönbeck U; Varo N; Murphy SA; Khera A; McGuire DK; Stanek G; Lo HS; Nuzzo R; Morrow DA; Peshock R; Libby P
    Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2192-6. PubMed ID: 16109925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Serum soluble CD40L level and its application in coronary heart disease].
    Li J; Peng DQ; Zhao SP
    Hunan Yi Ke Da Xue Xue Bao; 2003 Dec; 28(6):611-4. PubMed ID: 15804073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble CD40 ligand as a biomarker for storage-related preanalytic variations of human serum.
    Lengellé J; Panopoulos E; Betsou F
    Cytokine; 2008 Nov; 44(2):275-82. PubMed ID: 18851919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Changes and relations of soluble plasma CD40L and matrix metalloproteinase-9 levels in patients with coronary heart disease].
    Li J; Zhao SP; Peng DQ; Zhou HN
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Oct; 29(5):517-20. PubMed ID: 16137036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated circulating levels of soluble CD-40 ligand in haemodialysis patients with symptomatic coronary heart disease.
    Lim PS; Wu MY; Chien SW; Wu TK; Liu CS; Hu CY; Chang HC; Pai MA
    Nephrology (Carlton); 2008 Dec; 13(8):677-83. PubMed ID: 19019166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease.
    Türker S; Güneri S; Akdeniz B; Ozcan MA; Baris N; Badak O; Kirimli O; Yüksel F
    Am J Cardiol; 2006 Jan; 97(2):198-202. PubMed ID: 16442363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease.
    Mason PJ; Chakrabarti S; Albers AA; Rex S; Vitseva O; Varghese S; Freedman JE
    Am J Cardiol; 2005 Nov; 96(10):1365-9. PubMed ID: 16275179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating CD40 ligand is elevated only in patients with more advanced symptomatic peripheral arterial diseases.
    Lee WJ; Sheu WH; Chen YT; Liu TJ; Liang KW; Ting CT; Lee WL
    Thromb Res; 2006; 118(5):619-26. PubMed ID: 16356539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes.
    Tousoulis D; Antoniades C; Nikolopoulou A; Koniari K; Vasiliadou C; Marinou K; Koumallos N; Papageorgiou N; Stefanadi E; Siasos G; Stefanadis C
    Eur J Clin Invest; 2007 Aug; 37(8):623-8. PubMed ID: 17635572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between soluble CD40 ligand levels and Framingham coronary heart disease risk score in healthy volunteers.
    Verma S; Wang CH; Li SH; Lonn E; Charbonneau F; Title LM; Anderson TJ;
    Atherosclerosis; 2005 Oct; 182(2):361-5. PubMed ID: 16159609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble CD40 ligand:interleukin-10 ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarction.
    Dominguez-Rodriguez A; Abreu-Gonzalez P; Garcia-Gonzalez MJ; Kaski JC
    Thromb Res; 2007; 121(3):293-9. PubMed ID: 17521712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.